Amarin Calls For ITC Investigation Of Omega-3 Supplements
Law360, New York (August 30, 2017, 7:36 PM EDT) -- Amarin Pharma Inc. asked the U.S. International Trade Commission on Wednesday to investigate more than a dozen drug producers worldwide that it accused of falsely labeling their allegedly unapproved new drugs containing synthetically produced omega-3 acids as “dietary supplements.”
In its complaint, Amarin claimed that the companies had engaged in unfair trade practices and competition under the Tariff Act, the Lanham Act and the Federal Food, Drug, and Cosmetic Act by misleading consumers about the true nature of their drugs. Amarin also asserted that the companies were “freeriding” off the success of Amarin’s own drug, Vascepa, which is approved by the...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!